DIA Biosimilars Conference

Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts

September 23rd 2022

Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.

Better Patient Notification Is Needed to Improve Biosimilar Adoption

September 21st 2022

Article

Panelists at the DIA Biosimilars Conference discussed how biosimilars can help address health care disparities and why patient notification for switching to biosimilars must be handled with caution.

International Presenters Share Tips on Beefing Up Biosimilar Use

October 9th 2020

Article

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

FDA Reshuffles Priorities to Meet COVID-19 Trial Demand

October 7th 2020

Article

The FDA has had to rely on triaging to address its most critical priorities during the unfolding coronavirus disease 2019 (COVID-19) pandemic, according to Peter P. Stein, MD.

Lessons Learned From Denmark's Biosimilars Success

October 24th 2018

Article

Among European nations, Denmark has had some of the greatest success with leveraging biosimilars to reduce cost burdens on its healthcare system, and during the fifth DIA Biosimilars Conference, held October 22 to 23, 2018, in London, United Kingdom, stakeholders heard directly from Dorthe Bartels, MSc, on how Denmark has achieved its strong biosimilar uptake.

FDA's Leah Christl Provides an Update on the Biosimilar Action Plan

October 23rd 2018

Article

While it is indeed the case that the current administration has made drug pricing and biosimilars a priority, and while the Biosimilar Action Plan was hailed as a major step forward for biosimilars in the United States, “It’s not the only plan that’s going to exist,” said the FDA's Leah Christl, PhD.

The Challenge of Educating Patients on Biosimilars

October 23rd 2018

Article

While provider education on biosimilars presents a hurdle for health systems worldwide, patient education is also an area of significant need. During the fifth DIA Biosimilars Conference, held October 22 to 23 in London, United Kingdom, several stakeholders addressed this challenge.

What Do Providers Need to Know About Biosimilars?

October 22nd 2018

Article

With a number of new biosimilars making their way to market and eventually to the clinic, it is crucial that healthcare providers become educated about and comfortable with biosimilar products. During a session at the fifth DIA Biosimilars Conference, held October 22 to 23 in London, United Kingdom, experts addressed a number of key areas for provider education.

The Clinical Trials Landscape Is Evolving in Biosimilar Development

October 22nd 2018

Article

Among the hottest topics in biosimilar development is the future of clinical trials, and that fact was evident during the opening session of the fifth DIA Biosimilars Conference, held October 22 to 23 in London, United Kingdom. During the presentation, a review of the biosimilar regulatory framework, 4 experts explained the ways in which the landscape for clinical trials is evolving for biosimilars.